Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients

Atherosclerosis

Volumn 164, Issue 2, 2002, Pages 361-369

  Asztalos, Bela F ^a,d   Horvath, Katalin V ^a   McNamara, Judith R ^a   Roheim, Paul S ^b   Rubinstein, Joel J ^c   Schaefer, Ernst J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c NEWTON WELLESLEY HOSPITAL   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

Apolipoproteins; Coronary heart disease; HDL subpopulations; Lipids; Lipoproteins; Statins

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANALYTICAL PARAMETERS; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LOVASTATIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PRAVASTATIN; PROBABILITY; PYRROLES; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0036802354     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00149-1     Document Type: Article

References (35)

1. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation. 97:1998;1453-1460.
2. for the Cholesterol and Recurrent Events Trial Investigators, Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357.
4. for the West of Scotland Coronary Prevention Study Group, Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Eng. J. Med. 333:1995;1301-1307.
5. for the AFCAPS/TexCAPS Research Group, Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
6. Thompson G.R. What targets should lipid-modulating therapy achieve to optimize the prevention of coronary heart disease? Atheriosclerosis. 131:1997;1-5.
7. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 97:1998;946-952.
8. Miller G.J., Miller N.E. Plasma high density lipoprotein concentration and development of ischemic heart disease. Lancet. i:1975;16-19.
9. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
10. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: a meta-analysis of population-based studies. J. Cardiovasc. Risk. 3:1996;213-219.
11. Krauss R.M. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am. J. Med. 105:1998;48S-62S.
12. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler. Thromb. Vasc. Biol. 17:1997;107-113.
13. Eckardstein A., Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol. Curr. Opin. Lipidol. 11:2000;627-637.
14. Castelli W.P. Cholesterol and lipids in the risk of comnary artery disease: the Framingham Heart Study. Can. J. Cardiol. 8:1988;207-211.
15. Assmann G., Schulte H., von Eckardstein A., Huang Y. High density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 124:1996;S11-S20.
16. Asztalos B.F., Roheim P.S., Milani R.L., Lefevre M., McNamara J.R., Horvath K.V., et al. Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20:2000;2670-2676.
17. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients, Journal of Lipid Research, in press.
18. McNamara J.R., Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin. Chim. Acta. 166:1987;1-8.
19. Warnick G.R., Benderson J., Albers J.J. Dextran sulfate-Mg procedure for quantitation of high density lipoprotein cholesterol. Clin. Chem. 28:1982;1379-1388.
20. Nguyen T., Warnick G.R. Improved methods for separation of total HDL and subclasses. Clin. Chem. 35:1989;1086-1090.
21. McNamara J.R., Cole T.G., Contois J.H., Ferguson C.A., Ordovas J.M., Schaefer E.J. Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin. Chem. 41:1995;232-240.
22. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W.F., Massov T., Schaefer E.J. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidometric assay: results from the Framingham Offspring Study. Clin. Chem. 42:1996;515-523.
23. Asztalos B.F., Sloop C.H., Wong L., Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim. Biophys. Acta. 1169:1993;291-300.
24. Asztalos B.F., Lefevre M., Foster T.A., Tulley R., Widhauser M., Wong L., et al. Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations. Arterioscler. Thromb. Vasc. Biol. 17:1997;1885-1893.
25. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-2497.
26. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia. (The Curves Study). Am. J. Cardiol. 81:1998;582-587.
27. Branchi A., Fiorenzia A.M., Rovellini A., Torri A., Muzio F., Macor S., et al. Lowering effects of four different statins on serum triglyceride level. Eur. J. Clin. Pharmacol. 55:1999;499-502.
28. Davidson M, McKinney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R et al. for the Atorvastatin Study Group I. Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475.
29. Bertolini S., Bittolo B.G., Cambell L.M., et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 130:1997;191-197.
30. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39-44.
31. Fruchart J.C., Ailhaud G., et al. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin. Chem. 38:1992;793-797.
32. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered partical size distribution of apolipoprotein A-I containing lipoproteins in subjects with coronary heart disease. J. Lipid Res. 32:1991;383-394.
33. von Eckardstein A., Huang Y., Assmann G. Physiological role and clinical relevance of high density lipoprotein subclasses. Curr. Opin. Lipidol. 5:1994;404-416.
34. Guerin M., Lassel T.S., Le Goff W., Famier M., Chapman M.J. Action of atorvastatin in combined hyperlipidemia: referential reduction of cholesterol ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 20:2000;189-197.
35. O'Neill F.H., Patel D.D., Knight B.L., et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 21:2001;832-837.